CliffBio
small molecule

FLUORESCITE

FLUORESCEIN SODIUM

Loss of exclusivity—loss of exclusivity
CompanyAlcon →See this company's full patent-cliff portfolio

Drug detail

Brand nameFLUORESCITE
Active ingredientFLUORESCEIN SODIUM
StrengthEQ 500MG BASE/5ML (EQ 100MG BASE/ML)
Dosage formINJECTABLE
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalMarch 2006
Marketing statusRX

More from Alcon

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

FLUORESCITE patent cliff — loss of exclusivity — | CliffBio